Kevin Robert Lind - 30 Jun 2026 Form 4 Insider Report for Avalo Therapeutics, Inc. (AVTX)

Reporting relationship
Director
Issuer ticker
AVTX
Reported as of
30 Jun 2026
Net transaction value
$0
Source evidence Original filing metadata and source links for verification. 4 source fields
SEC form
4
Accepted by SEC
02 Jul 2026, 16:05:28 UTC
Prior SEC filing
04 Jun 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Christopher Sullivan, Attorney-in-Fact

Key filing fact

Kevin Robert Lind filed Form 4 for Avalo Therapeutics, Inc. (AVTX) on 02 Jul 2026.

Key facts

  • This page summarizes Kevin Robert Lind's Form 4 filing for Avalo Therapeutics, Inc. (AVTX).
  • 1 reported transaction and 1 derivative row are listed below.
  • Accepted by SEC: 02 Jul 2026, 16:05.

Change

  • Previous filing in this sequence was filed on 04 Jun 2026.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001677036 Primary reporting owner

Lind Kevin Robert

Relationship
Director
Address
C/O AVALO THERAPEUTICS, INC., 1500 LIBERTY RIDGE DRIVE, SUITE 321, WAYNE
Signature
/s/ Christopher Sullivan, Attorney-in-Fact
Signature date
02 Jul 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

AVTX transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares
+1,105
Change %
Price
$15.04*
Shares after
1,105
Date
30 Jun 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
1,105
Exercise price
$18.48
Footnotes
F1
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The options were granted on June 30, 2026, and are 100% vested.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .